In Down's syndrome screening using biochemical markers, the marker concentrations are adjusted for the gestational age of the fetus, since they are known to change with gestational age. This adjustment is performed by referring to the population median of each marker for the appropriate gestational age group. The measurement of gestational age is subject to error, whatever method is used, and the population median used is actually the median of a mixture of distributions for different true gestational ages. We show how the proportions in this mixture can be estimated and how the true median corresponding to a given true gestational age can be estimated. For simplicity, we consider the case of using a single marker, namely maternal serum o-fetoprotein, and show that the usual estimation method has considerable bias. The effect of this mixture on the calculation of patient-specific risks is discussed and we show that detection rates can be improved by allowing for this error in the dating process. The overall detection rate is increased by about 10/0. The increase in detection rate is age-dependent and for some maternal ages the increase is of the order of 5%. The comparative effects of different methods for dating are discussed.
SUMMARY. In Down's syndrome screening using biochemical markers, the marker concentrations are adjusted for the gestational age of the fetus, since they are known to change with gestational age. This adjustment is performed by referring to the population median of each marker for the appropriate gestational age group. The measurement of gestational age is subject to error, whatever method is used, and the population median used is actually the median of a mixture of distributions for different true gestational ages. We show how the proportions in this mixture can be estimated and how the true median corresponding to a given true gestational age can be estimated. For simplicity, we consider the case of using a single marker, namely maternal serum o-fetoprotein, and show that the usual estimation method has considerable bias. The effect of this mixture on the calculation of patient-specific risks is discussed and we show that detection rates can be improved by allowing for this error in the dating process. The overall detection rate is increased by about 10/0. The increase in detection rate is age-dependent and for some maternal ages the increase is of the order of 5%. The comparative effects of different methods for dating are discussed.
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The statistical procedure used when testing a fetus for risk of developing Down's syndrome in the second trimester relies on the reporting of a number of analyte concentrations as multiples of the median (MoMs). This procedure has become generally accepted because it is believed that by this method it is possible to remove the centreto-centre variation and the variation arising from the fact that the analytes measured vary with gestational age. I ,2 In an earlier paper, 3 we commented upon the problems associated with combining such MoM values; in particular we drew attention to the fact that when MoM values are combined from several sources, such as centres or gestational age groups, the result is a mixture distribution and not a Gaussian distribution as is usually assumed. This idea of mixtures led us to investigate the consequences to the screening procedure of errors in the dating process. In this paper we show that each group Correspondence: Dr B J Nix. 464 of fetuses of a given estimated gestational age (EGA) is actually a mixture of patients with different true gestational ages (TGA). The magnitude of the difference between the estimated and true gestational ages, and hence the degree of mixing, depends on the accuracy of the dating process. Hence, for any group of a given EGA, the distribution of analyte concentrations is actually a mixture distribution with components from different TGA groups. We show that failure to take these errors into account can lead to substantial errors in the estimation of the median for each age group and hence to errors in the calculation of the patient-specific risks which are derived from the medians. The extent of the misclassification leading to the mixture varies with the EGA and hence it is necessary to derive detection rates and false positive rates for each EGA group.
We use published figures':" on the errors in dating. The methods we propose enable us to compensate for the errors in gestational age Thus, correct classification occurs 77· 2% of the time, while an error of I week occurs 22' 8070 of the time.
For LMP dating the standard deviation is greater and this leads to greater misclassification probabilities. We find that (I) (2) Prob (EGA=x given TGA=x) =0,772 Prob (EGA =x± 1 given TGA =x) = 0·114 potential errors clearly depends on the errors in the dating process being used. This has been discussed by a number of authors. 5 ,9-11 The consensus is that the errors approximately follow a Gaussian distribution with a mean of zero and a standard deviation that depends on the dating method. For ultrasound, using the biparietal diameter (BPD), the standard deviation is approximately 2 days4,6,8 throughout the period 15-19 weeks, which is when the screening takes place in Gwent. If dating is based on the first day of the last menstrual period (LMP) then the standard deviation may be taken to be 7 days."
In the subsequent analysis we assume that, as is often the case, the EGA is recorded as a whole number of weeks. It is convenient to regard the TGA as being reported in a similar way. In many centres the EGA is recorded as a number of completed weeks plus a number of days. The methods we develop could be used in this situation too; the details will change but the basic principles still apply. In Appendix I we show how, under certain reasonable assumptions, it is possible to calculate what we term the misc/assijication distribution, that is the probability distribution followed by the EGA for a given TGA.
For ultrasound dating we find that assessment and as a result the detection rates resulting from these methods are better than those currently reported. The methods are illustrated on data derived from the Down's screening programme for Gwent, in South Wales, UK. There are 5080 test results, obtained between February 1990 and July 1991. All gestational ages were estimated by ultrasound. The policy in Gwent was to aim to screen at 16 weeks gestational age: if the gestational age at screening was thought to be less than 15 weeks, the screen was rescheduled for 16 weeks. Table I shows the numbers in each EGA group together with their median o-Ietoprotein (AFP) values. The standard deviations of the log-transformed data are also shown: the reasons for this transformation will be discussed later. Current screening practice involves the use of the so-called double or triple tests. In this paper we consider only a single analyte, maternal serum o-fetoprotein (MSAFP). The reasons for this are twofold. First, there is some disagreement over the extent of the correlation between the various analytes and this is clearly a relevant factor in the calculations. Secondly, the basic method for two or three analytes will follow the same lines but the mathematical details of risk calculation are more complicated. For simplicity, therefore, we have concentrated here on a single analyte and will be reporting later on the case of more than one analyte. The essential point is that the problems which arise from the misclassification are present however many analytes are used, and these problems must be addressed.
METHODS AND RESULTS

MiscIassification errors
The first step is to quantify the misclassification errors referred to above. The magnitude of Probability distribution for true gestational age Given the misclassification probabilities derived above, together with the observed distribution of the EGA, it is possible to estimate the distribution of the TGA. The details are given in Appendix 2. 16 weeks. As MSAFP levels tend to increase rapidly during this stage of pregnancy, most of the values come from a TGA distribution with a greater median than that for 15 weeks; the result will be to overestimate the median. Since the MoM values are calculated by dividing by the median, those which really are 15 weeks will have too small a MoM value. Similarly at, say, 18 weeks, a substantial proportion of the EGA values come from a TGA of 17 weeks. This will lower the median below its true value and will lead to MoM values being higher than they should be for this TGA group. The magnitude of this effect depends on the actual dating process used. It also depends on the size of the database used. The above calculations have used the expected proportions in the various groups: by their nature these are smooth. In reality the mechanism is a random one governed by the misclassification probabilities. The random variation associated with such processes will tend to produce even greater fluctuations. To illustrate this a simulation exercise was carried out whereby the individuals in each TGA group (group sizes were 5080 x TGA 
Mixture distribution
The effect of the misclassification, as was stated earlier, is that the distribution of MSAFP values for a given EGA is actually a mixture distribution, with components from different TGA values. We shall shortly see how it is possible to estimate the medians of the MSAFP values for different TGA values but first it is informative to consider the extent of the misclassification problem. In Appendix 2 (see Table 10 ) we show the joint distribution of EGA and TGA. By multiplying the entries in this table by 5080, the number of patients in our database, and inserting the values of the prior probabilities (Pi) from Table 2 and the misclassification probabilities, we obtain the expected numbers in each category. Figure 1 shows the complete classification into EGA groups by TGA value for BPD dating. It can be seen that there are very sizeable misclassifications at some of the dates; in fact the percentages of the EGA groups of 15,16, 17, 18 and 19 weeks which are misclassified are 74, 28, 8, 43 and 30, respectively.
If we are using LMP dating, then not surprisingly the results of the misclassification are even worse. Figure 2 shows the classification into groups using this dating. The percentages that are misclassified at the different EGAs are, in fact, 96,67,29, 79 and 82 for weeks 15, 16, 17, 18 and 19, respectively. This misclassification has major implications for the estimation of the median in each EGA group. For an EGA of 15 weeks, for example, the majority of patients have a TGA of at least
The results are shown in Table 2 , together with the observed and expected proportions of women in each EGA group; these expected proportions are calculated as shown in Appendix 2. As can be seen from the table, there is very good agreement between the observed and expected proportions in each EGA group. Further the estimated distribution of the TGA appears to be sensible. 
distribution) were allocated randomly between EGA groups according to the misclassification probabilities in equation (I). The coefficients of variation varied from 0·11170 for 16 weeks to 41170 at 15 weeks and 11·31170 at 20 weeks: these last two values are quite substantial. Proportionately these fluctuations will be even larger for a small database, such as that used when a laboratory is starting a screening programme. It would seem sensible, therefore, to suggest that the observed medians/means be smoothed in some appropriate manner before use to reduce this random fluctuation.
Estimation of true gestational age-dependent medians
As has been noted, the misclassifications will lead to the median at low gestational ages being overestimated and that at higher gestational ages to be underestimated. This will lead to bias in subsequent risk calculations. We now show how it is possible to estimate the true medians for each TGA, thus reducing this bias. Wald 1 asserted that the 10ge(MoM) values had a common Gaussian distribution, regardless of the gestational age group and screening centre, provided the appropriate medians have been used. In our earlier paper] we questioned this and suggested that departures from the Gaussian distribution, particularly in the tail regions, could be due to the mixing effect just described. In his paper Wald suggests that a suitable model for MSAFP levels of healthy fetuses is that 10ge(MoM(MSAFP» is N(0,0·461 2 ) and for Down's fetuses a suitable model is that 10&(MoM(MSAFP» is N( -0·3286, 0.461 2 ) , using N(p.,rr) to represent a Gaussian distribution with mean /L and standard deviation a. Denote by OM; the observed median for the group with an EGA of i weeks and by TM; the true median for the group with a TGA of i weeks. The MoM value calculated is MoM(MSAFP) = MSAFP/OM;, while the one that should be calculated is MSAFP/TM;. Following Wald we shall assume that 10ge(MSAFP/TM;) has a Gaussian distribution N(p.,rr) where p.= 0 for healthy fetuses. We need to estimate a number of parameters: TM; for each gestational age i weeks, the mean /Ld for Down's fetuses, and the common standard deviation a for Down's and healthy fetuses. The method for performing this estimation is described in Appendix 3 and the results for the estimated true values of the medians are shown in Table 3 and illustrated in Fig. 3 . The results follow the anticipated pattern, namely that the true medians are lower than those based on EGA groups for the lower EGA values, especially 15 weeks, while they are higher for higher EGAs such as 19 weeks. The standard deviation for each TGA group can also be easily estimated and these values are also shown in TGA = True gestational age. SD = 0·400 is the weighted average ofthe five estimates. FIGURE 3. Comparison of the estimated medians for each true gestational age (0) with the observed medians based on each estimated gestational age (GA) (e). TABLE 
Smoothed observed medians, estimated true medians and estimated true standard deviations (SD) of the maternal serum a-fetoprotein values (kU/L)for each true gestational age group
If the analysis were to be repeated using LMP dating, the effects would be even more pronounced, as we saw when comparing Figs I and 2. There would be greater differences between the true medians and those based on EGA groups. The analysis cannot be performed on our database, however, since all dating was performed using exclusively BPD dating.
Before examining the effect of these results on the detection rates we first consider how they affect the distributions of the MoM values. Using Wald's approach, the standard deviations of 10g.,(MoM(MSAFP» were virtually identical for Down's and healthy fetuses. The effects described above arise from the targeting procedure for referral, which is the same for both healthy and Down's fetuses, and so it seems reasonable to assume that the distribution of 10ge(X/TM;) is Table 3 . The final estimated value of a, the common standard deviation, is obtained by calculating a weighted average of these and is O'400. This is considerably lower than that quoted by Wald, namely 0·461. This is to be expected, since the contamination produced by the mixture process can only lead to increased variability within each EGA group.
TABI.E 4. Conditional distribution PI; of true gestational age (TGA) given estimated gestational age (EGA), together with the estimated means for Down's syndrome fetuses for each EGA (p.,J TGA (weeks) EGA (weeks) 15 16 17 18 19
Detection rates
The fundamental relationship on which all the screening policies are based'! is:
Posterior risk = Likelihood ratio X prior risk (3) Here the prior risk, rm' is the maternal agedependent prior risk for a mother of age m years. The prior age-dependent probability of a Down's fetus was taken by Wald et al,' to be
where m is the maternal age at delivery. The prior age-dependent risk is then
If Y=loge(MoM(MSAFP» is the score of a patient based on the MSAFP concentration, then the likelihood ratio LR ( Y) is given by
where fAy) andfh(Y) are the probability density functions of Y in the Down's and healthy populations, respectively. These are assumed to be Gaussian in form. Given the maternal age and MSAFP value, a value can be calculated for the posterior risk, R(y), say, using equation (3). If this exceeds some critical value, the patient is offered an amniocentesis. In Gwent this occurs if R(y» 1/300. In other centres a different critical value might be used. This condition is equivalent to saying that LR(y» 1/(300*r m )
The function U = LR( Y) is itself a random variable and probabilities associated with it can be calculated as described in Appendix 5. In this way the detection rate and false positive rate can be calculated.
Detection rate (DR) = Prob(U> 1/(300*r m ) given Down's fetus False positive rate (FPR) = Prob(U> 1/(300*r m > given healthy fetus Wald and Ow denoting the common standard deviation of Wald. From Wald's results, 0w=0'46I and IJ.wd= -0,3286. Using the above expressions we can calculate the detection rate DR m and false positive rate FPR m for a given maternal age m. These values are given as percentages in the first two rows of Table 5 . Now, since the observed median is in error, the MoMs should properly be calculated using the true median values. In Appendix 5 we show how to calculate DR tm and FPR tm , the detection and faIse positive rates for a woman aged m years with an EGA of t weeks. A selection of these values as percentages is shown in Tables 6 and 7. These can be averaged over the EGA distribution to obtain the average detection rate DR. m and false positive rate FPR' m for a given maternal age m. Table 5 . Note that the overall false positive rate using Wald's method is 5· 8OJo whereas that for the proposed method is 5·0%. By adjusting the critical value of the posterior risk to 11332, the overall false positive rate can be made equal to 5·8%: for this case the maternal age-dependent detection rate and false positive rate are shown in the last two rows of Table 5 . The overall detection rate is about 10, 70 higher, for the same false positive rate. The improvement offered by our method varies with maternal age and appears to be at its peak at a maternal age of 35 years, where there is a 5% improvement.
In a similar fashion we can calculate the average detection rate DR,. and false positive rate FPR,. for an EGA of t weeks. The details of how this is done are also given in Appendix 5. Tables 6 and 7 show the EGA-dependent rates DR'm and FPR'm for the range of maternal ages. It is clear that these vary markedly with maternal age and also that there is considerable variation between different EGA groups.
It is generally assumed that the maternal age distribution is independent of the EGA, and indeed that assumption has been made in deriving Table 5 . Using the Gwent database, the combined maternal age distribution is shown in Fig. 4 . Figure 5 shows the proportion of women over 40 in each EGA group and, as can be seen, this proportion tends to be higher in lower EGA groups. This is consistent with the belief that older women may be more eager to have their pregnancy confirmed and so present earlier, but we cannot make a general assertion about this. If the EGA and maternal age do turn out to be dependent, then the analysis presented will clearly require modification.
We do not possess a large database on Down's cases and so we are only able to compare the results 
of our methods with those currently in use for healthy fetuses. Thus, we shall concentrate on the false positive rates using our database of patients. Now the criterion for referring the patient, i.e. if the posterior risk is at least equal to a threshold, is equivalent to one of referring if the score S is less than or equal to some threshold, S~{). It is shown in Appendix 6 that, whatever the value of ex, the detection and false positive rates are the same, provided the correct threshold () is chosen. We can therefore choose any value of ex. A natural choice is ex= 1, giving S= V I5=XITMI 5 • For the example under discussion, () = O·554 in this instance: the value in practice will depend greatly on the actual database being used.
If the EGA for the patient is different from 15, the same argument applies, but the threshold will be different. Table 9 shows the thresholds for different EGAs, together with the consequent detection and false positive rates. If the EGA is 20 the situation is a little different since by our assumptions on dating errors the TGA cannot be 20. The discussion above shows that the actual score statistic is not crucial provided the correct threshold is used and so it seems sensible to use the true median at 19 weeks.
This approach gives an important comparison between Wald's method and that proposed here. To illustrate it consider again the case of a 30-year-old woman with an EGA of 15 weeks and a risk cut-off of 11300. Wald's approach determines a threshold by solving the equation LR(y)~1/(300 x rm)' Using Wald's parameters this gives a threshold value of 0'414. From 400 CONCLUSION estimated gestational age of the fetus.'? While it has been recognized that gestation dating is not exact, and some have attempted to estimate the effect of this variability on certain risk factors!" until now no one has fully quantified the effect of dating errors. We have shown how they affect the medians for different gestational age groups which in turn affect the calculations of the MoMs and the patient specific risks. The methods proposed here enable the true medians to be estimated, by identifying the true gestational agedependent distributions. Using the data from the Royal Gwent screening programme we found that the true medians could differ by as much as 14% from those currently being used, the discrepancy between the two sets of medians being greatest at the extremes of the gestational ages occurring in the screening programme. While these specific effects are consequences of the particular screening programme in use, the principles would apply to any programme. We have also demonstrated the implications of these findings on detection and false positive rates, which become dependent on the estimated gestational age and this dependence must be taken into account. All these effects affect the calculation of the patient-specific risks, and the errors associated with the conventional approach as exemplified by Wald,l which does not take dating errors into account, have been quantified. Finally, we have seen that it is possible to adjust the parameters used in Wald's approach to take account of dating errors.
As was stated at the outset, we have addressed here only the case of screening using a single analyte. Current screening practice uses two or three analytes. The methods described here could equally be applied to another analyte such as human chorionic gonadotrophin (hCG); to apply them to the full test requires study of the correlations between the analytes and the effect of dating error on the estimation of these correlations. We hope that the details of this will be reported later. Our presentation has been based around a particular screening programme and the details may well be different in other programmes. In particular in some cases gestational age may not be recorded in terms of whole numbers of weeks but to the nearest day. The same principles will apply in that situation. There will still be dating errors of the same magnitude which must be taken into account; these will extend over a much wider set of categories than before but the underlying rationale behind our methods is still valid. The results here are merely typical of those that might be obtained; the real importance is in Table 5 the detection rate and false positive rates can be found and are 8· 5% and 1·70/0 respectively. Using the methods of Appendix 6 it can be shown that to achieve these rates in this situation the actual risk threshold is not 11300 but rather 1/240. Thus the screening is identifying only a subset of those with a risk of more than 1 in 300. Such calculations can be made for any combination of maternal age and EGA. Figure 6 shows the true risk threshold for an EGA of 16 weeks as a function of maternal age, compared with the nominal level of 1/300. This shows that at low maternal ages the true risk threshold is higher than 11300, consistent with the fact that the detection and false positive rates were lower than with Wald's method, but at higher maternal ages the opposite is true. We believe that the estimate of risk proposed here is a more accurate estimate than would otherwise be obtained and that this is very important in a screening programme.
For many years changes in certain analyte concentrations have been measured against the FIGURE 6. The actual patient-specific posterior risk threshold (e) as a function of maternal age for a fetus with estimated gestational age 16 weeks compared with a nominal level of 1 in 300 (Wald threshold. 0). Ann Clin Biochem 1995: 32 highlighting the mechanisms that are at work in calculating estimates of risk. have undoubtedly improved the final version of this paper.
APPENDIX 1
Misclassification distribution Suppose that the EGA is recorded as a whole number of weeks; for analysis it is convenient to regard TGA in weekly units also. A patient whose true date is between x and x + 1 weeks will be where cP and <I> denote respectively the probability density function (pdt) and cumulative distribution function (edt) of a standard Gaussian distribution. The calculations can be carried out simply using a spreadsheet such as Excel.
APPENDIX 2
Probability distribution for true gestational age Let the true prior probabilities for TGA be denoted by PIS' •• P19' respectively. The details of their estimation depend to some extent on the screening policy adopted at a centre. The policy at the Royal Gwent Hospital is to reschedule any patients with dates less than 15 weeks for a return visit and blood test when they are 16 weeks. This rescheduling effect must be accounted for in the distribution of misclassification errors. Table 10 shows the joint distribution of EGA and TGA before any rescheduling. The distribution of misclassification probabilities is denoted by
where, for convenience, we assume that the misclassification can extend only up to 2 weeks. All elements in the rows with EGA= 14 or less must be moved into EGA = 16; the TGA must also be adjusted accordingly for this change. For example, the top left cell of Table 10 represents an EGA of 13 weeks and a TGA of 15 weeks on the original visit. The patient is required to return 3 weeks later with an EGA = 16 weeks. The TGA will also have advanced by three weeks so that the TGA on the return visit is 18 weeks. Table  11 shows the joint distribution of TGA and EGA after rescheduling. The marginal distribution of EGA (after rescheduling) can be found by summing each row corresponding to each EGA group of the Table  II assumed to be equal to that for healthy fetuses.
Since X has a log Gaussian distribution, we can write E(XITGA=i weeks) = TM, exp(p.d+o'-l2)
Wald observes that
where OMN, is the observed mean at an EGA of t weeks.
Using the law of total probability again, it follows that So estimates of !J.d can be obtained for each EGA group; the overall estimate is obtained from a weighted average of these.
APPENDIX 5
Calculation of false positive rates and detection rates Let the likelihood ratio However, the MoM (MSAFP) value used here has been calculated using the observed median; instead it should be calculated using the true median. If X, is the MSAFP reading for a randomly chosen patient with EGA of t weeks and a TGA of i weeks then OM, is the observed median at EGA t weeks and TM; is the true median at TGA i weeks.
It follows that the detection rate for a patient with an EGA of t weeks and a maternal age of m years (DR'm) is In a similar fashion, the DR and FPR for a given gestational age DR r . and FPR r . , respectively, can be found by averaging over the appropriate maternal age distribution i.e, as an appropriate threshold value 0 is chosen. Thus, a value of a can be chosen for convenience. The logical value is 1, i.e. we take the MoM value VIS at EGA 15 weeks. In this particular instance, the threshold 0 turns out to be 0·554. These conclusions apply to all EGA groups. The case when EGA is 20 weeks is slightly different since by the assumed prior distribution of TGA, there is no TGA of 20 weeks. Thus, at 20 weeks we would recommend that the median at 19 weeks be used using the appropriate threshold value.
It is interesting to note that the score S can be written as X/B, where B lies between TM 1S and TM I 6 , and since the observed median for an EGA of 15 lies between TM I S and TM I 6 , B could be made equal to the observed median for some choice of a. This would lead to S being Wald's score and so the method proposed here comes under the same framework. The threshold to be used is not that of Wald, however, but the one determined by the above method as otherwise the risk will not be at the correct level. It is clear from these expressions that the detection rates and false positive rates depend on the maternal age distribution at the centre performing the screening. This is independent of a and so each value of a must give rise to the same DR and FPR as long Ann Clin Biochem 1995: 32 
